[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE025705T4 - Tromboembolikus rendellenességek kezelése rivaroxabánnal - Google Patents

Tromboembolikus rendellenességek kezelése rivaroxabánnal

Info

Publication number
HUE025705T4
HUE025705T4 HUE06706291A HUE06706291A HUE025705T4 HU E025705 T4 HUE025705 T4 HU E025705T4 HU E06706291 A HUE06706291 A HU E06706291A HU E06706291 A HUE06706291 A HU E06706291A HU E025705 T4 HUE025705 T4 HU E025705T4
Authority
HU
Hungary
Prior art keywords
rivaroxaban
treatment
thromboembolic disorders
thromboembolic
disorders
Prior art date
Application number
HUE06706291A
Other languages
English (en)
Inventor
Frank Misselwitz
Dagmar Kubitza
Son-Mi Park
Klaus Wehling
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025705(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HUE025705T2 publication Critical patent/HUE025705T2/hu
Publication of HUE025705T4 publication Critical patent/HUE025705T4/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HUE06706291A 2005-01-31 2006-01-19 Tromboembolikus rendellenességek kezelése rivaroxabánnal HUE025705T4 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001893A EP1685841A1 (en) 2005-01-31 2005-01-31 Prevention and treatment of thromboembolic disorders

Publications (2)

Publication Number Publication Date
HUE025705T2 HUE025705T2 (hu) 2016-04-28
HUE025705T4 true HUE025705T4 (hu) 2023-02-28

Family

ID=34933512

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06706291A HUE025705T4 (hu) 2005-01-31 2006-01-19 Tromboembolikus rendellenességek kezelése rivaroxabánnal

Country Status (27)

Country Link
US (1) US9539218B2 (hu)
EP (2) EP1685841A1 (hu)
JP (1) JP2008528527A (hu)
KR (1) KR20070107009A (hu)
CN (1) CN101111236A (hu)
AR (2) AR052565A1 (hu)
AU (1) AU2006208613B2 (hu)
BR (1) BRPI0606760A2 (hu)
CA (1) CA2596145A1 (hu)
CY (1) CY1116494T1 (hu)
DK (1) DK1845961T3 (hu)
ES (1) ES2542335T3 (hu)
HR (1) HRP20150764T1 (hu)
HU (1) HUE025705T4 (hu)
IL (1) IL184585A0 (hu)
MA (1) MA29236B1 (hu)
MX (1) MX2007009100A (hu)
NO (1) NO344278B1 (hu)
NZ (1) NZ556765A (hu)
PL (1) PL1845961T3 (hu)
PT (1) PT1845961E (hu)
SG (1) SG159505A1 (hu)
SI (1) SI1845961T1 (hu)
TW (1) TWI377945B (hu)
UA (1) UA91355C2 (hu)
WO (1) WO2006079474A1 (hu)
ZA (1) ZA200706238B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
ATE502937T1 (de) 2005-10-04 2011-04-15 Bayer Schering Pharma Ag Neue polymorphe form von 5-chlor-n-(ä ( 5s )-2- 0x0-3-ä4-( 3-oxo-4-morpholinyl)-phenylü-1,3- oxazolidin-5-ylü -methyl)-2-thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
KR20120029428A (ko) 2009-06-16 2012-03-26 화이자 인코포레이티드 아픽사반의 투여 형태
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
EP2538360A1 (en) * 2011-06-16 2012-12-26 Koninklijke Philips Electronics N.V. Method of predicting a blood dilution risk value
JP2016529279A (ja) * 2013-08-29 2016-09-23 第一三共株式会社 がんの治療又は予防のための剤
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
KR20210040108A (ko) * 2018-07-30 2021-04-12 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물, 및 혈전절제술, 색전절제술 및 다른 혈관 질환 절차에 있어서의 이의 용도

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) * 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) * 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
US4977173A (en) * 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
ES2059467T3 (es) 1987-10-21 1994-11-16 Du Pont Merck Pharma Derivados de aminometil-oxooxazolidinil-etenilbenceno utiles como agentes antibacterianos.
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
DE69216251T2 (de) * 1991-11-01 1997-05-15 Pharmacia & Upjohn Co., Kalamazoo, Mich. Substituierte aryl- und heteroaryl-phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
EP0623615B1 (de) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
JPH10513446A (ja) * 1995-02-03 1998-12-22 ファルマシア・アンド・アップジョン・カンパニー ヘテロ芳香族環置換フェニルオキサゾリジノン抗微生物剤
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH11512386A (ja) 1995-09-01 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー ４−８員複素環へのｃ−ｃ結合を有するフェニルオキサゾリジノン
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
RU2183128C2 (ru) 1996-07-15 2002-06-10 Санкио Компани Лимитед Фармацевтическая композиция
US5935724A (en) * 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
SK156499A3 (en) 1997-05-30 2000-06-12 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US5977373A (en) * 1997-07-11 1999-11-02 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
ATE250054T1 (de) 1997-11-12 2003-10-15 Upjohn Co Oxazolidinone derivate und pharmazeutische zusammensetzungen
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
PL342243A1 (en) 1998-01-27 2001-06-04 Aventis Pharm Prod Inc Substituted oxoazaheterocyclic inhibitors of the factor xa
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
HUP0101958A3 (en) * 1998-05-18 2003-07-28 Upjohn Co Enhancement oxazolidinone antibacterial agents activity by using arginine derivatives
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
CN1221548C (zh) * 1999-12-21 2005-10-05 法玛西雅厄普约翰美国公司 含有砜亚氨基官能团的噁唑烷酮
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1245573A1 (en) 1999-12-28 2002-10-02 Ajinomoto Co., Inc. Aspartame derivative crystals
KR100415318B1 (ko) 2000-09-23 2004-01-16 탁승호 레이저를 이용한 수평 및 수직선 지시계
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) * 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
ATE502937T1 (de) 2005-10-04 2011-04-15 Bayer Schering Pharma Ag Neue polymorphe form von 5-chlor-n-(ä ( 5s )-2- 0x0-3-ä4-( 3-oxo-4-morpholinyl)-phenylü-1,3- oxazolidin-5-ylü -methyl)-2-thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006034916A1 (de) 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone

Also Published As

Publication number Publication date
IL184585A0 (en) 2008-12-29
AR110413A2 (es) 2019-03-27
SI1845961T1 (sl) 2015-08-31
EP1845961A1 (en) 2007-10-24
ZA200706238B (en) 2008-11-26
EP1845961B1 (en) 2015-04-22
TW200640441A (en) 2006-12-01
AU2006208613B2 (en) 2011-06-16
DK1845961T3 (en) 2015-07-20
AR052565A1 (es) 2007-03-21
NZ556765A (en) 2010-11-26
PL1845961T3 (pl) 2015-09-30
MA29236B1 (fr) 2008-02-01
TWI377945B (en) 2012-12-01
CN101111236A (zh) 2008-01-23
US20090004265A1 (en) 2009-01-01
WO2006079474A1 (en) 2006-08-03
ES2542335T3 (es) 2015-08-04
BRPI0606760A2 (pt) 2009-07-14
MX2007009100A (es) 2007-09-13
CA2596145A1 (en) 2006-08-03
PT1845961E (pt) 2015-08-31
CY1116494T1 (el) 2017-03-15
HRP20150764T1 (hr) 2015-08-28
NO20074356L (no) 2007-08-27
UA91355C2 (ru) 2010-07-26
KR20070107009A (ko) 2007-11-06
AU2006208613A1 (en) 2006-08-03
EP1685841A1 (en) 2006-08-02
NO344278B1 (no) 2019-10-28
JP2008528527A (ja) 2008-07-31
US9539218B2 (en) 2017-01-10
SG159505A1 (en) 2010-03-30
HUE025705T2 (hu) 2016-04-28

Similar Documents

Publication Publication Date Title
PL1845961T3 (pl) Leczenie rywaroksabanem zaburzeń zakrzepowo-zatorowych
HUS1900005I1 (hu) Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
PL1890684T3 (pl) Leczenie zaburzeń snu i czuwania
ZA200809528B (en) Treatment for depressive disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
ZA200809527B (en) Treatment for depressive disorders
IL186408A0 (en) Combination treatment methods
IL222557A (en) A compound for use in treating mutant disorders has ruled
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
HK1247943A1 (zh) 發育相關疾病的治療
IL193697A0 (en) Methods for treating cognitive and other disorders
GB2442365B (en) Methods of determining compounds useful in the treatment of bipolar disorders
GB0607952D0 (en) Novel treatment
EP2249837A4 (en) METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0525540D0 (en) New treatment
EP1871404A4 (en) ANTI-ASTHMATIC TREATMENT
GB0602857D0 (en) The treatment of sialorrhoea
ZA200806678B (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
GB0619218D0 (en) Treatment of conformational disorders
TJ27Y3 (en) Treatment methods of chronic mesotympanitis.
GB0518003D0 (en) Treatment of hepatatis c